EODData

LSE, 0RA2: Poxel SA

26 Dec 2025
LAST:

0.2390

CHANGE:
 0.00
OPEN:
0.2400
HIGH:
0.2400
ASK:
0.3495
VOLUME:
6.3K
CHG(%):
0.00
PREV:
0.2390
LOW:
0.2365
BID:
0.3165
 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
26 Dec 250.24000.24000.23650.23906.3K
25 Dec 250.24000.24000.23650.23906.3K
24 Dec 250.24000.24000.23700.23906.3K
23 Dec 250.24000.24000.23600.23604.8K
22 Dec 250.23700.23800.23700.2370275
19 Dec 250.24300.24300.24300.2430100
18 Dec 250.23800.23900.23600.23901.3K
17 Dec 250.24000.24300.23700.237021.4K
16 Dec 250.23900.23900.23900.2390917
15 Dec 250.25900.25900.24400.249011.0K

PROFILE

Name:Poxel SA
About:Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic diseases, type 2 diabetes, and liver diseases. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Address:Immeuble Le Sunway, Lyon, France, 69007
Website:https://www.poxelpharma.com

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

FUNDAMENTALS

Trailing P/E:-0.37 
Price to Sales:7.79 
Price to Book:-1.36 
Profit Margin:0.00 
Operating Margin:-21.34 
Return on Assets:-0.80 
Return on Equity:0.72 
EPS Ratio:-0.83 
Revenue:1.55M 
Shares:24.09M 
Market Cap:5.76M 

TECHNICAL INDICATORS

MA5:0.240.4%
MA10:0.240.3%
MA20:0.240.4%
MA50:0.2711.5%
MA100:0.3129.2%
MA200:0.4067.2%
STO9:42.86
STO14:41.67
RSI14:52.04
WPR14:-52.38
MTM14:0.01
ROC14:0.03 
ATR:0.01 
Week High:0.241.7%
Week Low:0.241.3%
Month High:0.56132.6%
Month Low:0.2267.2%
Year High:0.83246.9%
Year Low:0.1377.8%
Volatility:90.94